Published in Cancer Weekly, August 31st, 2004
Specific claims include compositions and methods for gene-based vaccination using immunogens or immunogen-encoding polynucleotides plus the Vaxfectin cationic lipid/co-lipid formulation.
The new patent is titled, "Adjuvant Compositions for Enhancing Immune Responses to Polynucleotide-Based Vaccines." It and other patents held by Vical are based on the company's discovery that administering polynucleotides, such as DNA or RNA, to tissues, without the use of viral delivery vehicles, may result in expression of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.